Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial-Reference-Cited by-同舟云学术

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

Published:2009-04 Issue:4 Volume:8 Page:334-344
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Collinge John,Gorham Michele,Hudson Fleur,Kennedy Angus,Keogh Geraldine,Pal Suvankar,Rossor Martin,Rudge Peter,Siddique Durre,Spyer Moira,Thomas Dafydd,Walker Sarah,Webb Tom,Wroe Steve,Darbyshire Janet

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference33 articles.

1. Prion diseases of humans and animals: their causes and molecular basis;Collinge;Annu Rev Neurosci,2001

2. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea;Collinge;Philos Trans R Soc Lond B Biol Sci,2008

3. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report;Wroe;Lancet,2006

4. Rational targeting for prion therapeutics;Mallucci;Nat Rev Neurosci,2005

5. A systematic review of prion therapeutics in experimental models;Trevitt;Brain,2006

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening of Anti-Prion Compounds Using the Protein Misfolding Cyclic Amplification Technology;Biomolecules;2024-09-04

2. Perspectives on CRISPR Genome Editing to Prevent Prion Diseases in High-Risk Individuals;Biomedicines;2024-08-01

3. Prion diseases motor and neuropsychiatric symptom cluster pharmacotherapy: structured scoping review;BMJ Supportive & Palliative Care;2024-07-26

4. Sigma Receptor Ligands Are Potent Antiprion Compounds that Act Independently of Sigma Receptor Binding;ACS Chemical Neuroscience;2024-05-14

5. Targeting Neuroinflammation by Pharmacologic Downregulation of Inflammatory Pathways Is Neuroprotective in Protein Misfolding Disorders;ACS Chemical Neuroscience;2024-03-20